← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ANTIMETABOLITES › Pyrimidine analogues
decitabine, combinations
L01BC58
Forms & Strengths
- Injection: 50 mg/mL
- Lyophilized powder for injection: 50 mg/vial
Adult Dosing
- Acute myeloid leukemia (AML): 20 mg/m² IV over 1 hour, daily for 5 days
- Myelodysplastic syndromes (MDS): 15 mg/m² IV over 1 hour, 3 times a day, for 3 days
Pediatric Dosing
- Not established for patients under 18 years old
Indications
- Treatment of adult patients with acute myeloid leukemia (AML)
- Treatment of adult patients with myelodysplastic syndromes (MDS)
Mechanism of Action
- Hypomethylating agent, inhibiting DNA methyltransferase
- Incorporation into DNA, causing DNA damage and apoptosis
Contraindications
- Hypersensitivity to decitabine or any component of the formulation
- Pregnancy and lactation
Adverse Reactions
- Myelosuppression (anemia, neutropenia, thrombocytopenia)
- Fatigue, nausea, vomiting, diarrhea
- Infections (pneumonia, sepsis), bleeding disorders
Drug Interactions
- Avoid concurrent use with other myelosuppressive agents
- Monitor for increased toxicity with concomitant use of other hepatotoxic or nephrotoxic agents
Curated Content: Needs Vetting Before Put to Clinical Use